Researchclopedia

Research Researchers Institutions Topics Submit About

Command Palette

Search for a command to run...

Researchclopedia

Research Researchers Institutions About

© 2026 Researchclopedia. Powered by OpenAlex under CC0 license.

Immutep (Germany) | Researchclopedia

Back to institutions

Immutep (Germany)

Leipzigcompany

44

Works

612

Citations

14

h-index

Top Research Topics

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses CAR-T cell therapy research

Top Researchers

Christian Mueller Universität Hamburg

1,111 works124,982 citationsh-index: 120

Recent Research

Abstract PS1-09-16: Optimal biological dose of eftilagimod alpha, a soluble LAG-3 protein, in metastatic breast cancer patients receiving weekly paclitaxel in AIPAC-003

N. K Ibrahim,I. Garcia Fructuoso,et al.

20260 citations

Ferroptosis and cancer prognosis

Colorectal and Anal Carcinomas

Immune Cell Function and Interaction

Pancreatic and Hepatic Oncology Research

Lung Cancer Treatments and Mutations

Esophageal Cancer Research and Treatment

Radiomics and Machine Learning in Medical Imaging

Lymphoma Diagnosis and Treatment

Head and Neck Cancer Studies

Frédéric Triebel Immutep (Germany)

267 works11,242 citationsh-index: 56

Malte Buchholz Philipps University of Marburg

216 works6,529 citationsh-index: 42

Sharron Gargosky TiGenix (Spain)

116 works3,795 citationsh-index: 33

Florian D. Vogl ETH Zurich

86 works2,919 citationsh-index: 22

Chrystelle Brignone

64 works2,385 citationsh-index: 18

Technical-pedagogical usability of digital inclusive reading support evolving through practice-to-research transfer

Ralf Junger,Judith Hanke

20250 citations

P3.18.34 TACTI-004, a Phase 3 Trial of Eftilagimod Alfa Plus Pembrolizumab (P) + Chemotherapy (C) vs Placebo + P + C in 1St Line NSCLC

M. Sebastian,Ina Nordman,et al.

20250 citations

Impact of Electrochemical Partitioning & Accelerator-Driven Transmutation of HAW on the Necessity for Deep Geological Storage

Georg J. Houben

20250 citations

TACTI-004: A double-blinded, randomized phase 3 trial in patients with advanced/metastatic non-small cell lung cancer receiving eftilagimod alfa (MHC class II agonist) in combination with pembrolizumab (P) and chemotherapy (C) versus placebo + P + C.

Giuseppe Lo Russo,Margarita Majem,et al.

20250 citations

Optimizing Cell Sourcing for Cell Therapy by Reducing Donor Variability with Recallable Leukopak Donors for Enhanced Standardization

Igor Gómez,J.M. Schäffer,et al.

20250 citations